© 2021 MJH Life Sciences and Drug Topics. All rights reserved.
© 2021 MJH Life Sciences™ and Drug Topics. All rights reserved.
July 08, 2021
The EMPEROR-Preserved study investigated empagliflozin (Jardiance; Eli Lilly) for the treatment of heart failure with preserved ejection fraction.
February 03, 2021
Pharmacists can help patients through education, therapy, and lifestyle modifications.
January 28, 2021
The latest Heart Disease and Stroke Statistical Update highlighted pandemic-related trends that may impact cardiovascular disease mortality for years.
January 22, 2021
Investigators compared outcomes among patients with COVID-19 and hypertension through modifying blood pressure medication use.
December 17, 2020
An FDA panel voted to recommend the expanded use of sacubitril/valsartan (Entresto; Novartis).
October 12, 2020
A key opinion leader discusses the most significant unmet needs in the evolving spectrum of cardiovascular risk management.
September 08, 2020
A discussion on recent data updates from the REDUCE-IT trial, and their practical implications for physicians managing cardiovascular risk.
September 01, 2020
An expert physician discusses the role of agents that reduce triglyceride levels and the potential on cardiovascular risk.
August 14, 2020
A discussion on which factors to consider when assessing the need for management/reduction of cardiovascular risk.
A key opinion leader discusses effective risk prevention measures and challenges to reducing adverse events. He also considers effective educational resources for self-care.